Observational Study for Patients With Hypertrophic Cardiomyopathy

NCT04851652 | Unknown

• 1 other identifier: GDREC2019545HR1
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Observational study on patients with hypertrophic cardiomyopathy aims to investigate the correlation between cardiac fibrosis, as indicated by cardiac magnetic resonance, and the prognosis, and further to explore biomarkers for cardiac fibrosis and adverse prognosis of hypertrophic cardiomyopathy. Therefore, endpoints including all-cause mortality, cardiovascular death, ventricular arrythmia, non-fatal stroke, non-fatal myocardial infarction, sudden death, successful cardiopulmonary resuscitation will be evaluated.

Conditions

HCM - Hypertrophic Cardiomyopathy

Keywords

all-cause mortality; cardiovascular death; hospitalization for heart failure

Outcome Measures

Primary Outcomes (1)

• All-cause death

  All-cause mortality refers to death from any causes.

  5 YEARS

Secondary Outcomes (8)

• Cardiovascular death

  5 YEARS

• Ventricular tachycardia

  5 YEARS.

• Ventricular fibrillation and flutter

  5 YEARS.

• nonfatal stroke

  5 YEARS.

• nonfatal myocardial infarction

  5 YEARS.

Interventions

No intervention nor exposure OTHER

As an observational study, no intervention nor exposure is interested.

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with hypertrophic cardiomyopathy by medical history, physical examination and echocardiography.

You may qualify if:

• Patients diagnosed with hypertrophic cardiomyopathy by medical history, physical examination and echocardiography.

You may not qualify if:

• Patients with cardiac hypertrophy caused by other factors such as hypertension, diabetes, myocardial amyloidosis, mitochondria cardiomyopathy, congenital heart disease, valvular heart disease, etc; Patients who had underwent heart transplatation; Individuals not suitable for the present study due to maligant tumor or severe trauma will be excluded.

Sponsors & Collaborators

• Guangdong Provincial People's Hospital: lead

Study Sites (1)

Guangdong cardiovascular institute

Guangzhou, Guangdong, 510080, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

plasma, serum, whole blood, and white blood cells

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic

Condition Hierarchy (Ancestors)

Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases

Study Officials

• Cheng Huang, PhD

  Guangdong Cardiovascular institute

  STUDY DIRECTOR

Central Study Contacts

Cheng Huang, PhD

CONTACT

020-83827812; linfeng7822@sina.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD

Study Record Dates

• First Submitted: April 11, 2021
• First Posted: April 20, 2021
• Study Start: June 1, 2021
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: April 20, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)